Soligenix reaches contract over thermostabilization technology

Soligenix and the University of Colorado have recently completed a licensing contract for a novel vaccine thermostabilization technology that the firm has been developing for its ricin toxin subunit vaccine candidate RiVax, as well as a subunit vaccine for the prevention of anthrax.

The new deal supersedes Soligenix’s previous option-to-license deal. This means the firm can use the platform for developing biodefense vaccines and other potential vaccines, according to

The technology is capable of keeping sensitive vaccine components in their original configuration and represents a step up in vaccine creation technology.

“The achievement of extended stability under elevated temperature would represent a significant step forward in vaccine technology,” Robert N. Brey, the CEO of Soligenix said, reports. “Lack of long-term stability is a significant problem in vaccines for use in emergency situations and especially for vaccines used in the developing world where the cold storage chain is difficult to maintain.

“Further, this novel thermostability technology has the potential to allow us to expand our vaccine business into the development of countermeasures against other more common infectious diseases.”

Soligenix is focused on the development of biodefense vaccines for civilian and military applications, as well as for life-threatening conditions such as graft-versus-host disease and cancer, reports.

RiVax is currently in Phase I development. Soligenix received a $9.4 million grant from the National Institute of Allergy and Infectious Diseases to help the development of the thermostable vaccine for RiVax and other rapidly acting vaccines.